Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma

Inclusion Criteria: * Informed consent as documented by signature. * Cat-dander-induced ARC as confirmed by patient history and type-1-sensitization to cat dander in skin and/or serum. Exclusion Criteria: * Hypersensitivity to phenol. * Planned depot steroid injection for treatment of ARC * Patients with uncontrolled asthma or FEV1 \< 70% of the predicted value in adults (after adequate pharmacological therapy). * Patients with a severe asthma exacerbation in the past 3 months. * Irreversible secondary changes in the affected organ (e.g., emphysema, bronchiectasis). * Chronic obstructive or restrictive lung disease. * Patients with active systemic autoimmune diseases and patients with immune deficiencies or immune weaknesses. * Severe chronic inflammatory diseases. * Concomitant infection with fever or other signs/symptoms of an acute or chronic infection at treatment visit. * Chronic obstructive or restrictive lung disease * Patients with malignant tumours that currently have clinical significance. * Disease or conditions rendering the treatment of anaphylactic reactions difficult (symptomatic coronary heart diseases, severe arterial hypertension, and treatment with beta-blockers). * Known cardiovascular disease, i.e., not even NYHA class I. * Use of ACE-blockers. * Recent or on-going hepatic or renal disease. * Severe chronic renal insufficiency (due to aluminium burden). * Alcohol or drug abuse * Women who are pregnant and breast feeding * Women of childbearing age who wish to become pregnant or do not use contraception. * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant. * Participation in another study with investigational drug within the 30 days preceding and during the present study.